Success Stories: Pioneering Cancer Researcher from Myanmar Earns EB1A Approval Through NAILG’s Expertise

Client’s Testimonial:

“Thank you for all your effort and guidance throughout the EB1A process. I’m happy to share my experience and refer others to your firm.”

On July 14^th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Hematology and Oncology Fellow in the Field of Medicine (Approval Notice).

General Field: Medicine

Position at the Time of Case Filing: Hematology and Oncology Fellow

Country of Origin: Myanmar

State of Residence at the Time of Filing: New York

Approval Notice Date: July 14^th, 2025

Processing Time: 3 months, 27 days (Premium Processing Requested)

Case Summary:

NAILG is delighted to announce the EB1A (Alien of Extraordinary Ability) approval for a hematology and oncology fellow from Myanmar, whose groundbreaking research in cancer immunotherapy has positioned him among the leading experts in medicine. This approval, secured through premium processing, underscores both the exceptional merit of his work and the strength of our legal strategy.

The client’s research focuses on improving the safety and efficacy of immune checkpoint inhibitor (ICI) therapies for cancer patients with pre-existing autoimmune conditions—an underserved group often excluded from clinical trials. His work has yielded pivotal insights, showing that while autoimmune disease flares can occur, most are manageable, and certain patient groups—such as those with non-small cell lung cancer—may experience significant tumor reduction with ICIs. His expertise spans additional domains, including developing digital interventions for chronic disease management and enhancing liver cancer screening through improved doctor-patient communication.

With 10 peer-reviewed journal articles and 13 conference abstracts to his credit, his publications appear in top-tier journals. His findings have been cited 575 times and have shaped cancer care strategies across many countries. He has conducted at least 10 reviews for leading journals and conferences, further validating his authority in the field. His work has attracted recognition and collaboration from prestigious institutions worldwide, and he has secured funding for innovative research, including a clinical trial combining ICIs with therapies to reduce autoimmune flare risks.

One recommendation letter captured the essence of his contributions:

“By advancing safer and more effective treatment options, his groundbreaking work not only aligns with our national goals to improve cancer care but also firmly establishes him as a leader in cancer research.”

In our petition, we demonstrated that his original scientific contributions are of major significance, substantiated by exceptional citation metrics, top-tier publications, widespread adoption of his methods, and endorsements from globally recognized experts. This compelling evidence positioned him as one of the rare individuals at the pinnacle of his field.

Through this successful EB1A petition, NAILG has once again enabled a distinguished researcher to continue vital work in the United States, where his expertise will directly benefit national and global cancer treatment efforts.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.